SCGB3A2

Across TCGA pan-cancer cohorts, SCGB3A2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SCGB3A2 data layer compared with 27 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher SCGB3A2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SCGB3A2 expression acts as an unfavorable survival marker.

READ, ESCA, and SKCM are the cancer types where SCGB3A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	DFS	Median	All	0.059	0.845	<.001	36	view →
ESCA	DFS	Median	All	0.045	0.533	<.001	12	view →
SKCM	OS	Median	All	0.350	0.788	.003	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SCGB3A2–READ (DFS)

Open the READ breakdown →